Hypertension 2010: what was new for the cardiologist?

Bibliography

• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007;370:829-40
   PubMed Web of Science ®Google Scholar
• The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008;372:1174-83
   PubMedGoogle Scholar
• Beckett NS, Peters R, Fletcher AE, ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Staessen JA, Angeli F, Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009;374:525-33
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group, Cushman WC, Evans GW, Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85
   PubMed Web of Science ®Google Scholar
• NAVIGATOR Study Group, McMurray JJ, Holman RR, Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-90
   PubMed Web of Science ®Google Scholar
• ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009;361:1953-62
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Price JF, Stewart MC, Aspirin for prevention of cardiovascular events in a general population screened for a Low Ankle Brachial Index A Randomized Controlled Trial. JAMA 2010;303:841-8
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
   PubMed Web of Science ®Google Scholar
• Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-62
   PubMed Web of Science ®Google Scholar
• Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007;99:1006-12
   PubMed Web of Science ®Google Scholar
• Schneider MP, Hua TA, Bohm M, Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010;55:2299-307
   PubMed Web of Science ®Google Scholar
• Baguet JP, Robitail S, Boyer L, A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs 2005;5:131-40
   PubMedGoogle Scholar
• Wald DS, Law M, Morris JK, Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
   PubMed Web of Science ®Google Scholar
• Havranek EP, Froshaug DB, Emserman CD, Left ventricular hypertrophy and cardiovascular mortality by race and ethnicity. Am J Med 2008;121:870-5
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Cavallini C, The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens 2009;27:1697-704
   PubMed Web of Science ®Google Scholar
• Bombelli M, Facchetti R, Carugo S, Left ventricular hypertrophy increases cardiovascular risk independently of in- and out-of office blood pressure values. J Hypertens 2009;27:2458-64
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Hennig M, Hollweck R, Baseline values but not treatment induced changes in carotid intima media thickness predict incident cardiovascular events in treated hypertensives. Findings in the ELSA. Circulation 2009;120:1084-90
   PubMed Web of Science ®Google Scholar
• Inoue M, Maeda R, Kawakami H, Aortic pulse wave velocity predicts cardiovascular mortality in middle-aged and elderly Japanese men. Circ J 2009;73:549-53
   PubMed Web of Science ®Google Scholar
• Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Aortic blood pressure and survival study group. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension 2008;51:848-55
   PubMed Web of Science ®Google Scholar
• Mitchell GF, Hwang SJ, Vasan RS, Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010;121:505-11
   PubMed Web of Science ®Google Scholar
• Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12
   PubMed Web of Science ®Google Scholar
• Matsushita K, Selvin E, Bash LD, Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010;55:648-59
   PubMed Web of Science ®Google Scholar
• Kahn R, Buse J, Ferrannini E, The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304
   PubMed Web of Science ®Google Scholar
• Sundstrom J, Vallhagen E, Riserus U, Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care 2006;29:1673-4
   PubMedGoogle Scholar
• Mente A, Yusuf S, Islam S, Metabolic syndrome and risk of acute myocardial infarction. A case-control study of 26 903 subjects from 52 countries. J Am Coll Cardiol 2010;55:2390-8
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38
   PubMed Web of Science ®Google Scholar
• Genser B, Grammer TB, Stojakovic T, Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis. Int J Clin Pharmacol Ther 2008;46:497-510
   PubMedGoogle Scholar
• Okin PM, Devereux RB, Jern S, Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9
   PubMed Web of Science ®Google Scholar
• Ibsen H, Olsen MH, Wachtell K, Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J Nephrol 2008;21:566-9
   PubMedGoogle Scholar
• de Galan BE, Perkovic V, Ninomiya T, Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-92
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Borgioni C, Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003;16(11 Pt 1):895-9
   PubMedGoogle Scholar
• Kearney-Schwartz A, Rossignol P, Bracard S, Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke 2009;40:1229-36
   PubMed Web of Science ®Google Scholar
• O'Donnell MJ, Xavier D, Liu L, Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; DOI:10.1016/S0140-6736(10)60834-3
   Google Scholar
• Schrier RW, Estacio RO, Esler A, Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
   PubMed Web of Science ®Google Scholar
• Julius S, Nesbitt SD, Egan BM, Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685-97
   PubMed Web of Science ®Google Scholar
• Luders S, Schrader J, Berger J, The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008;26:1487-96
   PubMed Web of Science ®Google Scholar
• van den Bogaard B, Baumann M, van Weert HC, Study on the temporary treatment of high normal blood pressure for the prevention of hypertension and hypertensive organ damage: the TIResiAS-study. Ned Tijdschr Geneeskd 2007;151:1800-2
   PubMedGoogle Scholar
• Howard BV, Roman MJ, Devereux RB, Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008;299:1678-89
   PubMed Web of Science ®Google Scholar
• Mancia G, Messerli F, Bakris G, Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007;50:299-305
   PubMed Web of Science ®Google Scholar
• Messerli FH, Mancia G, Conti CR, Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-93
   PubMed Web of Science ®Google Scholar
• Mancia G, Messerli F, Bakris G, Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007;50:299-305
   PubMed Web of Science ®Google Scholar
• Sleight P, Redon J, Verdecchia P, Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009;27:1360-9
   PubMed Web of Science ®Google Scholar
• Redon J, Sleight P, Mancia G, Safety and efficacy of aggressive blood pressure lowering among patients with diabetes: subgroup analyses from the ONTARGET trial. J Hypertens 2009;27(Suppl 4):S16
   Google Scholar
• Zanchetti A, Mancia G, Black HR, Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009;27:946-7
   Google Scholar
• Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009;27:923-34
   Google Scholar
• K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 2004;43:(5 Suppl 1):S1-290
   Web of Science ®Google Scholar
• Bielecka-Dąbrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010. [Epub ahead of print]
   Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG, Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE, Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-36
   PubMed Web of Science ®Google Scholar
• Munzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009;54:1491-9
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Cohen-Solal A, Bohm M, Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150-8
   PubMed Web of Science ®Google Scholar
• Cleland JG. Beta-blockers for heart failure: why, which, when, and where. Med Clin North Am 2003;87:339-71
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR, The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Kaplan NM. The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide. Hypertension 2009;54:951-3
   PubMed Web of Science ®Google Scholar
• Bakris G, Molitch M, Zhou Q, Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr 2008;3:18-25
   PubMedGoogle Scholar
• Yusuf S, Diener HC, Sacco RL, Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-37
   PubMed Web of Science ®Google Scholar
• Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006;114:838-54
   PubMed Web of Science ®Google Scholar
• Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004;43:1343-7
   PubMed Web of Science ®Google Scholar
• Janke J, Schupp M, Engeli S, Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens 2006;24:1809-16
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Zinman B, Sheridan P, Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care 2010;33:608-13
   PubMedGoogle Scholar
• Solomon SD, Wang D, Finn P, Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004;110:2180-3
   PubMed Web of Science ®Google Scholar
• Sipahi I, Debanne SM, Rowland DY, Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; DOI:10.1016/S1470-2045(10)70106-6
   Google Scholar
• Julius S, Kjeldsen SE, Weber MA. Angiotensin-receptor blockade and the risk of cancer. Omission of VALUE trial data invalidates conclusions [letter to the editor]. Not yet published
   Google Scholar
• Bakris G, Molitch M, Hewkin A, Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592-7
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Ferrari R, Remme WJ, Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J 2010;159:795-802
   PubMedGoogle Scholar
• Bakris GL, Sarafidis PA, Weir MR, Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81
   PubMed Web of Science ®Google Scholar
• Retraction – Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2009;374:1226
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang Y, Liu G, The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005;23:2157-72
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Bond MG, Hennig M, Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA) – a randomized, double-blind, long-term trial. Circulation 2002;106:2422-7
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
   PubMed Web of Science ®Google Scholar
• Boger-Megiddo I, Heckbert SR, Weiss NS, Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ 2010;340:c103
   Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Feldman RD, Zou GY, Vandervoort MK, A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009;53:646-53
   PubMed Web of Science ®Google Scholar
• Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 2002;4:343-9
   PubMed Web of Science ®Google Scholar
• Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-24
   PubMed Web of Science ®Google Scholar
• The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009;373:1341-51
   PubMedGoogle Scholar
• Somes GW, Pahor M, Shorr RI, The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999;159:2004-9
   PubMed Web of Science ®Google Scholar
• Tveit A, Grundvold I, Olufsen M, Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007;120:85-91
   PubMed Web of Science ®Google Scholar
• GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-17
   PubMed Web of Science ®Google Scholar
• Zeller T. Renal artery stenosis: epidemiology, clinical manifestation, and percutaneous endovascular therapy. J Interv Cardiol 2005;18:497-506
   PubMedGoogle Scholar
• Textor SC. Current approaches to renovascular hypertension. Med Clin North Am 2009;93:717-32
   PubMed Web of Science ®Google Scholar
• Ives NJ, Wheatley K, Stowe RL, Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. Nephrol Dial Transplant 2003;18:298-304
   PubMed Web of Science ®Google Scholar
• Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998;31:823-9
   PubMed Web of Science ®Google Scholar
• van Jaarsveld BC, Krijnen P, Pieterman H, The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 2000;342:1007-14
   PubMed Web of Science ®Google Scholar
• Bax L, Woittiez AJ, Kouwenberg HJ, Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 2009;150:840-8: W150-1
   PubMed Web of Science ®Google Scholar
• Symonides B, Gaciong Z. The effect of percutaneous revascularization of atherosclerotic renal artery stenosis on blood pressure. A meta-analysis of randomized trials. J Hypertens 2010;28(Suppl A):E510
   PubMedGoogle Scholar
• Ridker PM, Danielson E, Fonseca FA, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Eng J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• de Lorgeril M, Salen P, Abramson J, Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 2010;170:1032-6
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Erqou S, Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010;170:s1024-31
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group, Ginsberg HN, Elam MB, Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
   PubMed Web of Science ®Google Scholar
• Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009;15:MS1-5
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I, The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840
   PubMed Web of Science ®Google Scholar
• Pignone M, Alberts MJ, Colwell JA, Aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association, a scientific statement of American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;121:2878-86
   Google Scholar
• Petursson H, Getz L, Sigurdsson JA, Hetlevik I. Current European guidelines for management of arterial hypertension: are they adequate for use in primary care? Modelling study based on the Norwegian HUNT 2 population. BMC Fam Pract 2009;10:70
   PubMed Web of Science ®Google Scholar
• Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension 2009;53:480-6
   PubMed Web of Science ®Google Scholar